ProShare Advisors’s Dyne Therapeutics DYN Stock Holding History

ProShare Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$484K	Sell	26,683 -2,243	-8%	-$38.7K	﹤0.01%	1087
2025 Q4	$566K	Buy	28,926 +5,185	+22%	+$98.2K	﹤0.01%	1069
2025 Q3	$300K	Buy	23,741 +251	+1%	+$2.86K	﹤0.01%	1420
2025 Q2	$224K	Buy	23,490 +294	+1%	+$3.24K	﹤0.01%	1651
2025 Q1	$243K	Sell	23,196 -4,848	-17%	-$69.3K	﹤0.01%	1558
2024 Q4	$661K	Buy	28,044 +6,862	+32%	+$203K	﹤0.01%	1113
2024 Q3	$761K	Buy	21,182 +6,012	+40%	+$239K	﹤0.01%	898
2024 Q2	$535K	Sell	15,170 -1,137	-7%	-$33K	﹤0.01%	940
2024 Q1	$463K	Buy	16,307 +5,028	+45%	+$114K	﹤0.01%	1137
2023 Q4	$150K	Buy	+11,279	New	+$110K	﹤0.01%	1708
2022 Q2	–	Sell	-10,966	Closed	-$105K	–	1886
2022 Q1	$105K	Sell	10,966 -2,853	-21%	-$24.3K	﹤0.01%	2019
2021 Q4	$163K	Buy	+13,819	New	+$194K	﹤0.01%	2097

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

ProShare Advisors's DYN Position: Q1 2026 in Review

ProShare Advisors reduced its Dyne Therapeutics (DYN) stake by 7.8% in Q1 2026, selling an estimated $38.7K and leaving 26,683 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

ProShare Advisors first reported a position in DYN in Q4 2021 and has held it in 12 quarters since. The position peaked at $761K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

ProShare Advisors held 26,683 shares of Dyne Therapeutics worth $484K as of Q1 2026.
ProShare Advisors sold 2,243 Dyne Therapeutics shares in Q1 2026, an estimated $38.7K.
Dyne Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1087 holding.
ProShare Advisors first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 12 quarters since.
ProShare Advisors's Dyne Therapeutics position peaked at $761K in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.